Phase I study to assess tolerability, safety and PK of MGB-BP-3 in healthy volunteers

A new class of antibiotic, MGB-BP-3, is about to be tested for safety in healthy human volunteers for the first time. This matters because existing antibiotics are losing their power against dangerous bacteria. The drug works through a novel mechanism that, according to the researchers, should not trigger bacterial resistance—a growing crisis in hospitals worldwide. The first target is *Clostridium difficile*, a gut infection that causes severe diarrhoea and kills thousands of patients each year, often after they have taken other antibiotics. If the safety study succeeds, MGB-BP-3 could become a frontline treatment for C. diff infections, replacing drugs that are increasingly failing. The same drug platform also shows promise against MRSA and other life-threatening infections where current treatments are becoming less effective. This would directly affect hospital wards, where resistant infections already force longer stays, more expensive care, and higher death rates. The grant from Innovate UK funds the human safety study—a critical step before larger trials can begin.